Experience

Arsenal Biosciences, Inc.

• United States
• Biotechnology Research
• 100 - 200 Employee

• Principal Scientist

  • Sep 2022 - Present

• Sr. Scientist II

  • Mar 2021 - Present

• Senior Scientist

  • Nov 2020 - Mar 2021

  South San Francisco, California, United States Preclinical development



Prolynx

• United States
• Biotechnology
• 1 - 100 Employee

• Scientific Consultant

  • Aug 2020 - Nov 2020

  San Francisco Bay Area



Eureka Therapeutics, Inc

• United States
• Biotechnology Research
• 1 - 100 Employee

• Research Scientist III, group leader, project lead

  • Feb 2020 - Aug 2020

  • Lead several pipeline platform development projects, including one IND filing ready pipeline. • Manage a direct report of the project team in the initiation and execution of laboratory experimentation

• Research Scientist II, group leader, project lead

  • Feb 2018 - Feb 2020

  Emeryville, USA • Technology development of a gamma/delta TCR-based ARTEMIS AbTCR platform 1) A major player in the ARTEMIS AbTCR technology platform development. 2) Develop different assays to screen and identify a proprietary co-stimulatory domain to optimize ARTEMIS /CAR platform to make more potent, tumor-infiltrating, and efficacious T cells against solid tumors 3) Contribute to multiple proprietary technologies to improve CAR-T activity. • Pipeline development 1) Conduct cell panning… Show more • Technology development of a gamma/delta TCR-based ARTEMIS AbTCR platform 1) A major player in the ARTEMIS AbTCR technology platform development. 2) Develop different assays to screen and identify a proprietary co-stimulatory domain to optimize ARTEMIS /CAR platform to make more potent, tumor-infiltrating, and efficacious T cells against solid tumors 3) Contribute to multiple proprietary technologies to improve CAR-T activity. • Pipeline development 1) Conduct cell panning and screening with phage displays to identify multiple antibody leads for CAR-T targeting. 2) Lead and execute in vitro and in vivo assays to screen and develop an ARTEMIS-based TCR-T pipeline drug into IND-filing phase for T cells therapy 3) Manage a direct report of the project team in the initiation and execution of laboratory experimentation 4) Process development of T cell cultivation to produce memory subset-enriched T cells.

• Research Scientist II

  • May 2017 - Jan 2018

  Emeryville

• Research Scientist

  • Nov 2016 - Apr 2017

  Emeryville



Adheren Inc.

• Sr. Scientist

  • Jan 2016 - Aug 2016

  United States Target identification and validation in preclinical research focusing on cancer T cell therapy • Coordinated development, optimization and characterization of human and cynomologus monkey T cells and CIKs • In vitro (FACS, LDH assay etc.), and in vivo (cyno autologous killing model) evaluation of Adheren's T cell therapy candidates in liquid and solid tumor cell therapy



ALSTEM, INC

• United States
• Biotechnology
• 1 - 100 Employee

• Sr. Scientist, group leader

  • Nov 2012 - Dec 2015

  • R & D in stem cell technology and virus packaging systems • Developed the virus production enhancer, ViralBoost, a top seller • Key role in developing xeno-free iPSC freezing medium • Contributor to xeno-free iPSCs dissociation medium development • Custom reprogramming human somatic cells such as fibroblasts, LCL and PMBC into iPSCs by using episomal vector under feeder and feeder free condition • Custom CRISPR/Cas9 gene editing in mammalian… Show more • R & D in stem cell technology and virus packaging systems • Developed the virus production enhancer, ViralBoost, a top seller • Key role in developing xeno-free iPSC freezing medium • Contributor to xeno-free iPSCs dissociation medium development • Custom reprogramming human somatic cells such as fibroblasts, LCL and PMBC into iPSCs by using episomal vector under feeder and feeder free condition • Custom CRISPR/Cas9 gene editing in mammalian cells • Designed and cloned customer CRISPR gRNAs, and designed and constructed donor vectors • Conducted customer cell line engineering for knock-out, knock-in and point mutation applications • Custom lenti/retro viral packaging. • Custom neural progenitor cell differentiation from iPSCs • Custom primary cell immortalization Show less



Novartis

• Switzerland
• Pharmaceutical Manufacturing
• 700 & Above Employee

• Scientist II

  • Dec 2011 - Jun 2012

  Emeryville Target validation in preclinical cancer research • Packaging target gene-shRNA carrying lentivirus • Inducible target gene-shRNA screening • shRNA knockdown of target gene in certain cancer cell lines • Validating cancer target gene by different approach: • Cell proliferation assay • Clonogenic assay • Spheroid assay



UC San Diego

• United States
• Higher Education
• 700 & Above Employee

• Postdoctoral Fellow

  • Aug 2009 - Sep 2011

  La Jolla, CA, USA Investigating the effect of GPCRs and cyclic AMP (cAMP) on cardiac fibroblasts. • Isolated and cultured primary rat and mouse cardiac fibroblasts. • Implemented GPCR array to look for novel GPCRs involved in cardiac fibrosis in mouse. • Conducted different approaches such as real-time PCR and Western blotting to determine how cAMP suppresses cardiac fibrosis by assessing the expression of pro-fibrotic cytokines by myofibroblasts in the absence and presence of agents that increase… Show more Investigating the effect of GPCRs and cyclic AMP (cAMP) on cardiac fibroblasts. • Isolated and cultured primary rat and mouse cardiac fibroblasts. • Implemented GPCR array to look for novel GPCRs involved in cardiac fibrosis in mouse. • Conducted different approaches such as real-time PCR and Western blotting to determine how cAMP suppresses cardiac fibrosis by assessing the expression of pro-fibrotic cytokines by myofibroblasts in the absence and presence of agents that increase intracellular cAMP levels in rat/mouse cardiac fibroblasts. • Designed and executed MTT assay, FACS-related methods to indentify the cardiac fibroblast cell death induced by cAMP and the downstream pathway in which cAMP is involved. • Using siRNA knockdown to study the effect of Bcl-2 interacting mediator (Bim) on the cAMP induced cell death in cardiac fibroblasts. • Investigated cAMP/PKA signaling pathway in Cytotoxic T lymphocyte antigen-2 alpha induces apoptosis of mouse cardiac fibroblasts by implementation of siRNA gene silencing and viral transduction of exogenous gene expression to determine the pro-apoptotic effect Cytotoix T lymphocyte antigen-2 alpha on cardiac fibroblasts. Show less



University of Bristol

• United Kingdom
• Higher Education
• 700 & Above Employee

• PhD graduate student

  • Oct 2003 - Jan 2009

  Bristol, UK Studied the characterization of ADP-ribosylation factor like protein 8b (Arl8b) • Designed, produced and purified recombinant Arl8b protein and its mutants from E. coli. • Investigated the GTP/GDP binding activity of Arl8b by using [3H] GDP and [35S] GTPγS. • Produced exogenous Arl8b protein and its mutants stably or transiently in mammalian cells, following by immunofluorescence and cell imaging to determine the localization and function of Arl8b. • Implemented different… Show more Studied the characterization of ADP-ribosylation factor like protein 8b (Arl8b) • Designed, produced and purified recombinant Arl8b protein and its mutants from E. coli. • Investigated the GTP/GDP binding activity of Arl8b by using [3H] GDP and [35S] GTPγS. • Produced exogenous Arl8b protein and its mutants stably or transiently in mammalian cells, following by immunofluorescence and cell imaging to determine the localization and function of Arl8b. • Implemented different purification such as immunoprecipitation (IP), GST pull down and tandem affinity purification (TAP) of recombinant Arl8b from mammalian cells to look for its interacting proteins. Took part in the study of the cellular function of centaurin-alpha1/2. • Produced and purified recombinant centaurin-alpha 1/2 from E. coli. • Implemented dot blot assay to assess the centaurin- alpha 1/2 binding affinity to phosphatidylinositol (PI) 3-kinase lipid products. Show less



Jinan University

• China
• Education Administration Programs
• 400 - 500 Employee

• Research Associate

  • Aug 2001 - Jun 2003

  Guangzhou, China Conducted the study of controlled DNA sequences by Pem protein in male reproductive tissue of mammalian systems (National Sciences Funding). • Produced and purified recombinant Pem protein from E. coli. • Generated anti- Pem antibody in rabbit Vice lab manager • Took part in the procurement of lab equipment and chemicals • Handled daily operation of the lab including organizing lab meetings and activities as well as maintaining equipment • Supervised undergraduates… Show more Conducted the study of controlled DNA sequences by Pem protein in male reproductive tissue of mammalian systems (National Sciences Funding). • Produced and purified recombinant Pem protein from E. coli. • Generated anti- Pem antibody in rabbit Vice lab manager • Took part in the procurement of lab equipment and chemicals • Handled daily operation of the lab including organizing lab meetings and activities as well as maintaining equipment • Supervised undergraduates for their graduate projects • Trained graduate student in PCR base techniques. Show less



Jinan University

• China
• Education Administration Programs
• 400 - 500 Employee

• MSc. graduate student

  • Sep 1998 - Jun 2001

  Guangzhou, China Discovered novel gene markers of pregnancy-induced hypertension in Chinese Han population (National Sciences Funding). Designed and executed PCR and RFLP-related methods to investigate gene markers of pregnancy-induced hypertension. Extracted white blood cell DNA from the blood samples of control group and pregnancy-induced hypertension group.